Tenfibgen-DMAT nanocapsule delivers CK2 inhibitor DMAT to prostate cancer xenograft tumors causing inhibition of cell proliferation

Janeen H. Trembley, Gretchen M. Unger, Omar Cespedes Gomez, Md J. Abedin, Vicci L. Korman, Rachel I. Vogel, Gloria Niehans, Betsy T. Kren, Khalil Ahmed

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

CK2 is a master regulator protein kinase which demonstrates heightened expression in diverse cancer types and is considered a promising target for therapy. Given its ubiquitous expression and potent influence on cell survival, cancer celldirected targeting of the CK2 signal is an important factor for development of an anti-CK2 therapeutic. We previously reported on the malignant cell specificity and effect on CK2 signaling of a tenfibgen (TBG) based nanocapsule for delivery of the CK2 small molecule inhibitor 2-dimethylamino- 4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) in cultured prostate cancer cells. Here we tested the ability of TBG-DMAT to affect the growth of prostate xenograft tumors in mice. Our results show that treatment of PC3-LN4 xenograft tumors with TBG-DMAT caused loss of proliferative Ki-67 signal as well as Nuclear Factor-kappa B (NF-κB) expression in the tumors. Further, the TBG-DMAT nanocapsule was detected in tumors and not in liver or testis. In conclusion, TBG-based nanocapsule delivery of anti-CK2 small molecule drugs holds significant promise for treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)15-25
Number of pages11
JournalMolecular and Cellular Pharmacology
Volume6
Issue number2
DOIs
StatePublished - Jan 1 2014

Keywords

  • CK2
  • DMAT
  • Nanocapsule
  • Nanoparticle
  • Prostate cancer
  • Tenfibgen

Fingerprint Dive into the research topics of 'Tenfibgen-DMAT nanocapsule delivers CK2 inhibitor DMAT to prostate cancer xenograft tumors causing inhibition of cell proliferation'. Together they form a unique fingerprint.

Cite this